Trust Co. of Toledo NA OH Takes $203,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Trust Co. of Toledo NA OH purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 867 shares of the medical instruments supplier’s stock, valued at approximately $203,000.

Other large investors have also bought and sold shares of the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. DiNuzzo Private Wealth Inc. acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $30,000. Scarborough Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $32,000. Finally, Accordant Advisory Group Inc bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $35,000. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the topic of several recent analyst reports. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Evercore ISI decreased their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price on the stock. Finally, StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Stock Down 0.1 %

Becton, Dickinson and Company stock traded down $0.27 during trading hours on Tuesday, hitting $235.51. 1,276,286 shares of the stock traded hands, compared to its average volume of 1,459,890. The company has a market cap of $68.06 billion, a PE ratio of 51.87, a PEG ratio of 2.06 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $233.05 and its two-hundred day moving average price is $236.30. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $284.48.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the company posted $2.96 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 13.06 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total transaction of $781,209.00. Following the transaction, the executive vice president now owns 11,308 shares in the company, valued at approximately $2,676,942.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold a total of 6,900 shares of company stock valued at $1,634,112 in the last quarter. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.